Market Place
Sourcing Support
XBiotech Study Suggests Breakthrough For Advanced Pancreatic Cancer
18 Jun 2024 //
GLOBENEWSWIRE
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
04 Jan 2024 //
GLOBENEWSWIRE
Dr. Alan Kivitz to Chair XBiotech™s Natrunix Program in Rheumatoid Arthritis
14 Nov 2023 //
GLOBENEWSWIRE
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin
26 Sep 2023 //
GLOBENEWSWIRE
XBiotech Announces Enrollment Completion of Ph II, Placebo Controlled
30 Aug 2023 //
GLOBENEWSWIRE
XBiotech Announces First Patient Begins Novel Natrunix Therapy in PII RA Trial
08 Aug 2023 //
GLOBENEWSWIRE
XBiotech Commences Tender Offer to Purchase $80,000,000 Worth of Its Shares
17 May 2023 //
GLOBENEWSWIRE
XBiotech Announces First Patient Enrolled French(INCA) Ph I/II/III Natrunix™
13 Oct 2022 //
GLOBENEWSWIRE
XBiotech Successfully Completes PI portion of Pancreatic Cancer Study
20 Jun 2022 //
GLOBENEWSWIRE
XBiotech Announces ANSM Approval, INSA funding for PII/III Study for Natrunix
28 Apr 2022 //
GLOBENEWSWIRE
Why Are XBiotech Shares Trading Higher Today
28 Apr 2022 //
BENZINGA
XBiotech Begins Enrollment in Phase I Trial for Arthritis Therapy Natrunix-SQ
26 Jan 2022 //
GLOBENEWSWIRE
FDA genehmigt IND-Antrag von XBiotech im Bereich Rheumatologie
13 Dec 2021 //
GLOBENEWSWIRE
XBiotech to Launch Novel Candidate Therapy for Stroke
28 Oct 2021 //
GLOBENEWSWIRE
Dr. Benjamin Musher will lead the PI/II trial evaluating Natrunix
09 Sep 2021 //
GLOBENEWSWIRE
Dr. Benjamin Musher to Chair PI/II Study for XBiotech’s anti-cancer Natrunix
08 Sep 2021 //
GLOBENEWSWIRE
XBiotech Announces Arrival of Dr. Mark Ziats, MD Ph.D., as Medical Director
30 Aug 2021 //
GLOBENEWSWIRE
XBiotech Announces Dividend to Common Shareholders
12 Jul 2021 //
GLOBENEWSWIRE
XBiotech Announces Dividend to Holders of Common Stock
06 Jul 2021 //
GLOBENEWSWIRE
XBiotech Announces Receipt of $75 Million from Sale of Antibody
30 Jun 2021 //
GLOBENEWSWIRE
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001
23 Jun 2021 //
GLOBENEWSWIRE
XBiotech Developing True Human Antibody Combination as Candidate Treatment
21 Sep 2020 //
GLOBENEWSWIRE
XBiotech Identifies “Super Bloods” for the Development of a True Human™
01 May 2020 //
GLOBENEWSWIRE
XBiotech & BioBridge Global Collaborate on FDA Program to Dev Potential COVID-19
03 Apr 2020 //
APNEWS
Foresee-X Augment Reality solution from Surglasses registered US FDA & ready
31 Dec 2019 //
PHARMABIZ
Janssen to Acquire Investigational Bermekimab from Xbiotech
06 Dec 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.